Biotech Values

[jq1234]

I think the correlation between TURQUOISE-1 and 2 is same study design, 12-wk arm vs 24-wk arm, one for cirrhosis patients, one for HIV co-infection, as they are now because all other registration trials exclude cirrhosis patients and HIV patients. It's natural to have one study for each of these excluded patients, cirrhosis and HIV. For whatever reason we don't know, TURQUOISE-1 started well after TURQUOISE-2.